Wilson’s disease (WD) is an autosomal recessive disorder of copper metabolism caused by ATP7B mutations, characterized by hepatic copper accumulation and multisystem involvement. Several rare inherited and acquired conditions can closely mimic WD, posing diagnostic challenges and the risk of inappropriate therapy. By examining neuroimaging patterns and distinguishing between diagnostic criteria, this narrative review provides a comprehensive synthesis of WD-mimicking disorders, emphasizing their molecular mechanisms, clinical phenotypes, and biochemical features. WD-mimicking disorders encompass ATP7A-related neurodegenerations (Menkes disease, occipital horn syndrome, X-linked distal hereditary motor neuropathy), MEDNIK syndrome, Huppke–Brendel syndrome, aceruloplasminemia, congenital disorders of glycosylation, primary familial intrahepatic cholestasis type 3, and acquired copper deficiency syndromes. Mechanisms include systemic copper deficiency, impaired intracellular trafficking, defective ceruloplasmin biosynthesis, secondary hepatic copper accumulation, and abnormal glycosylation. Clinical features range from neurodevelopmental delay, movement disorders, and hepatic dysfunction to dermatologic, hematologic, and connective-tissue abnormalities. Biochemical profiles may overlap with WD, particularly low serum ceruloplasmin and total copper, altered urinary copper excretion, and elevated hepatic copper in some disorders. Neuroimaging and genetic testing provide critical discriminative value. Management is largely supportive, with disease-specific therapies available in selected conditions, such as subcutaneous copper in Menkes disease or monosaccharide supplementation in certain congenital disorders of glycosylation subtypes. Accurate differentiation between WD and WD-mimicking disorders requires careful integration of clinical, biochemical, imaging, and molecular data. Recognition of distinctive features and understanding underlying pathophysiology are essential to avoid misdiagnosis and inappropriate anti-copper therapy, optimize management, and improve patient outcomes.
Despite many years of extensive research into the etiology and treatment of Alzheimer’s disease, based on the importance of amyloid and tau protein as causative factors, these studies have stalled, have not brought any breakthroughs and, most importantly, have not led to any final conclusions. Therefore, the ineffectiveness of the above-mentioned actions and the pressure from the community of people affected by Alzheimer’s disease forced the scientific community to change its way of thinking about the etiopathogenesis of this disease. This situation has prompted a group of scientists who have been studying the effects of brain ischemia for years to focus on post-ischemic changes, which–similarly to Alzheimer’s disease–predominate in the hippocampus, leading to the development of amyloid plaques, neurofibrillary tangles and ultimately to dementia. In this context, it has been proposed that brain ischemia may play an important role in driving amyloid and tau protein pathology in the development of Alzheimer’s disease. In this review, we present an update of extensive experimental and clinical studies conducted over several years on the role of brain ischemia in the neuropathogenesis of Alzheimer’s disease. Current advances in understanding the ischemic etiology of Alzheimer’s disease have revealed dysregulation of Alzheimer’s disease-associated genes, including secretases, amyloid precursor protein, apoptosis, autophagy, mitophagy, tau protein, α-synuclein, apolipoproteins, LRP1, and RAGE. This article presents the relationship between genes which dysregulation is a result of brain ischemia and the cellular and tissue neuropathology characteristic of Alzheimer’s disease and their proteins. These observations clearly indicate that, following brain ischemia, changes occur in the expression of Alzheimer’s disease-associated genes and in the folding of disease-associated proteins such as amyloid, tau protein, and α-synuclein. This leads to massive neuronal death and disruption of the neuronal network, ultimately leading to the development of Alzheimer’s disease-like dementia. Data indicate common genomic and proteomic factors in brain ischemia and Alzheimer’s disease. It seems that the brain ischemia model may be useful in determining the role of folding proteins and their genes dysregulation in Alzheimer’s disease. In the future, manipulation of genes and proteins associated with ischemia and ischemia-induced Alzheimer’s disease will likely provide new hope for developing causal therapies that are urgently needed to prevent or treat Alzheimer’s disease. The innovative/novel approach to the etiology of Alzheimer’s disease presented in this review will provide stakeholders with a glimpse into the future.
Introduction The use of benzodiazepine receptor agonists (BZRA) is associated with increased risks of falls, fractures, hospitalisations and mortality, particularly in older adults, causing substantial patient harm and healthcare costs across Europe. Despite well-established safety concerns and limited effectiveness for sleep problems, BZRA remain widely prescribed. Although previous interventions, including those initiated in hospital settings, reduced BZRA use under study conditions, evidence on patient-relevant outcomes is limited and implementation in real-world European healthcare settings remains scarce. The BE-SAFE (Implementing a patient-centred and evidence-based intervention to reduce BEnzodiazepine and sedative-hypnotic use to improve patient SAFEty and quality of care) trial evaluates whether a theory-based, hospital-initiated, deprescribing intervention increases BZRA discontinuation without compromising sleep quality in older adults treated for sleep problems, compared with usual care.Methods and analysis BE-SAFE is a multicentre, parallel group, cluster-randomised controlled trial conducted in inpatient and outpatient hospital settings across six European countries (Belgium, Greece, Norway, Poland, Spain and Switzerland). The trial assesses superiority for BZRA discontinuation and non-inferiority for sleep quality. Recruitment started in December 2024. Patients aged >= 65 years who have used BZRA for sleep problems on average >= 3 times per week for the preceding 3 months are eligible. Clusters are defined at the hospital physician level and are randomised 1:1 to usual care or the multicomponent, theory-based deprescribing intervention. The intervention includes senior-physician endorsement; BZRA deprescribing training (including shared decision-making); a structured deprescribing algorithm; self-monitoring; patient and caregiver educational materials (including cognitive behavioural therapy for insomnia); and structured communication with community healthcare professionals. The co-primary outcomes are BZRA discontinuation and sleep quality at 12 months. Secondary outcomes include BZRA discontinuation or dose reduction, withdrawal symptoms and sleep quality, health-related quality of life, standardised daily BZRA dose and use of substitute sleep medication; adverse effects (falls, fractures, delirium, hospitalisations and mortality). The target sample size is 470 participants across 62 clusters.Methods and analysis BE-SAFE is a multicentre, parallel group, cluster-randomised controlled trial conducted in inpatient and outpatient hospital settings across six European countries (Belgium, Greece, Norway, Poland, Spain and Switzerland). The trial assesses superiority for BZRA discontinuation and non-inferiority for sleep quality. Recruitment started in December 2024. Patients aged >= 65 years who have used BZRA for sleep problems on average >= 3 times per week for the preceding 3 months are eligible. Clusters are defined at the hospital physician level and are randomised 1:1 to usual care or the multicomponent, theory-based deprescribing intervention. The intervention includes senior-physician endorsement; BZRA deprescribing training (including shared decision-making); a structured deprescribing algorithm; self-monitoring; patient and caregiver educational materials (including cognitive behavioural therapy for insomnia); and structured communication with community healthcare professionals. The co-primary outcomes are BZRA discontinuation and sleep quality at 12 months. Secondary outcomes include BZRA discontinuation or dose reduction, withdrawal symptoms and sleep quality, health-related quality of life, standardised daily BZRA dose and use of substitute sleep medication; adverse effects (falls, fractures, delirium, hospitalisations and mortality). The target sample size is 470 participants across 62 clusters.Methods and analysis BE-SAFE is a multicentre, parallel group, cluster-randomised controlled trial conducted in inpatient and outpatient hospital settings across six European countries (Belgium, Greece, Norway, Poland, Spain and Switzerland). The trial assesses superiority for BZRA discontinuation and non-inferiority for sleep quality. Recruitment started in December 2024. Patients aged >= 65 years who have used BZRA for sleep problems on average >= 3 times per week for the preceding 3 months are eligible. Clusters are defined at the hospital physician level and are randomised 1:1 to usual care or the multicomponent, theory-based deprescribing intervention. The intervention includes senior-physician endorsement; BZRA deprescribing training (including shared decision-making); a structured deprescribing algorithm; self-monitoring; patient and caregiver educational materials (including cognitive behavioural therapy for insomnia); and structured communication with community healthcare professionals. The co-primary outcomes are BZRA discontinuation and sleep quality at 12 months. Secondary outcomes include BZRA discontinuation or dose reduction, withdrawal symptoms and sleep quality, health-related quality of life, standardised daily BZRA dose and use of substitute sleep medication; adverse effects (falls, fractures, delirium, hospitalisations and mortality). The target sample size is 470 participants across 62 clusters.Ethics and dissemination Ethics approval was obtained from all participating centres: CHU UCL Namur, site Godinne (approval number: NUB0392024000049 - 111/2024, Belgium); CHU UCL Namur, site St. Elisabeth (approval number: NUB0392024000049 - 19/2024, Belgium); CHU UCL Namur, site Dinant (approval number: NUB0392024000049 - 5/2025, Belgium); Bioethics Committee of the Institute of Psychiatry and Neurology (approval number: 10/2024, Poland); Regional Committee for Medical and Health Research Ethics (approval number: REK s & oslash;r-& oslash;st C - 722845, Norway); Ethics Committee of Eginition Hospital, Laikon Hospital, Sotiria Hospital and Ippokratio Hospital (approval numbers respectively: 1217/02-08-2024, 606/03-09-2024, 3532/10-02-2026 and 65/16-07-2024, Greece); the Commission on Ethics in Animal and Human Experimentation (CEEAH) of the Universitat Aut & ograve;noma de Barcelona (approval number: 6221, Spain); Ethics Committee of Germans Trias i Pujol Hospital of Badalona (approval number PI-24-206, Spain); the Ethical Committee of the Canton of Bern (approval number: BASEC2024-00702, Switzerland). Results will be disseminated through peer-reviewed journals and presentations at scientific conferences.Trial registration number ClinicalTrials.gov (NCT06584513); Swiss National Clinical Trials Portal (HumRes65897 | SNCTP000006133 | BASEC2024-00702).
Deep brain stimulation (DBS) is an established neurosurgical therapy for movement disorders, neuropsychiatric conditions, and drug-resistant epilepsy. Intracranial hemorrhage (ICH) remains among the most severe complications of DBS, with limited data on its risk factors. This study aims to assess the incidence of ICH and evaluate associated non-surgical and selected surgical risk factors in a large, single-center cohort. We retrospectively analyzed 683 patients (1227 DBS electrodes implanted) treated at a single medical center between November 2008 and April 2025. Data on demographics, diagnoses, comorbidities, and surgical techniques were collected and analyzed using both statistical and descriptive methods to identify predictors of ICH. ICH were classified as symptomatic (transient or permanent) or asymptomatic based on clinical outcomes. ICH occurred in 34 patients (4.98